Dr. Adam Kadlec

Dr. Adam Kadlec
Dr. Adam Kadlec is the System Medical Director for Innovation and a practicing Urologist at Advocate Aurora Health. Dr. Kadlec earned his undergraduate and medical degrees with high honors at the University of Wisconsin-Madison. He went on to complete residency training at Loyola University Medical Center in Chicago, where he received the Silbar Award, given annually to the outstanding Chief Resident in the North Central Section of the American Urological Association (AUA). Dr. Kadlec then completed a fellowship in Endourology and Minimally Invasive Surgery, also at Loyola, with a focus in complex endoscopy, percutaneous renal surgery, and laparoscopy/robotics. Throughout his career, Dr. Kadlec has published and presented clinical research at both the regional and national levels, and he is a principal investigator at the Advocate Aurora Research Institute. He has been a peer reviewer for the Journal of Urology and was on the review panel for the AUA Guideline on Medical Management of Kidney Stones. Dr. Kadlec is active in the AUA, currently serving as the Section Chair of the Young Urologist Committee. Dr. Kadlec has a deep interest in biomedical innovation and entrepreneurship. In addition to his Medical Director role at Advocate Aurora Health, he is also involved in ongoing development of medical devices in Urology. He has been a consultant to digital health and medical technology companies and is an active member of the healthcare committee for Golden Angels Investors in Milwaukee. His innovation-related articles have appeared in national publications, including NEJM Catalyst and Doximity Op-(M)ed.

Languages Spoken:


Medical School:

University of Wisconsin


Loyola University Medical Center - Urology


Loyola University Medical Center - Minimally Invasive Surgery


University of Wisconsin

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only